Cargando…
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Mepolizumab (Nucala(®)) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently Na...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498675/ https://www.ncbi.nlm.nih.gov/pubmed/28721009 http://dx.doi.org/10.2147/BTT.S93954 |